Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires

Giulia Bramato1,2, Roberta Barone1, Maria Rosaria Barulli1, Chiara Zecca1, Rosanna Tortelli1, Marco Filardi1,3† and Giancarlo Logroscino1,3*†

Abstract
Background: The 3-item SARC-F (SARC-F-3) and the 5-item Mini Sarcopenia Risk Assessment (MSRA-5) questionnaires have been recently proposed to screen elderly people regarding the risk of sarcopenia. However, no studies have investigated their performances in Alzheimer’s disease (AD).

Methods: We conducted a single-center observational study, including 130 consecutive AD patients (mean age: 70.71 ± 8.50 y, 54.6% women) who attended a center for neurodegenerative diseases. Sarcopenia was diagnosed using the European Working Group on Sarcopenia in Older People of 2010 (EWGSOP1) and of 2018 (EWGSOP2) criteria. Sensitivity, specificity, positive and negative likelihood ratio, and the area under the receiver operating characteristic curve (AUC) were used to assess the diagnostic performance of SARC-F-3 and MSRA-5.

Results: SARC-F-3 showed a sensitivity of 9.7%, a specificity of 82.8% and an AUC of 0.41 using EWGSOP1, whereas the sensitivity was of 16.7%, specificity of 84.7% and AUC of 0.58 using EWGSOP2. The MSRA-5 displayed a sensitivity of 3.2%, a specificity of 89.9% and an AUC of 0.41 using EWGSOP1, whereas sensitivity was of 0%, specificity of 91.1% and the AUC of 0.55 using EWGSOP2 criteria. The questionnaires showed a moderate agreement (Cohen’s k = 0.53).

Conclusions: In our sample of AD patients, a sizable number of sarcopenic individuals were misidentified by SARC-F-3 and MSRA-5, making those questionnaires unsuitable for sarcopenia screening. Considering that sarcopenia has a high prevalence in dementia and that its correct and timely identification is paramount for optimal management of patients, the development and validation of an ad-hoc sarcopenia screening tool for AD patients is highly desirable.

Keywords: Sarcopenia, Screening, Elderly, SARC-F-3, MSRA-5, Alzheimer’s disease

Background
Sarcopenia is a progressive and generalized skeletal muscle disorder, due to adverse muscle changes that occur over the course of life, characterized by loss of muscle mass, muscle strength and/or physical performance [1]. Sarcopenia is commonly observed among elderly but can also occur earlier in life [2]. The estimated prevalence of sarcopenia in community-dwelling older adults varies from 9.9 to 40.4%, depending on the definition adopted and has been show that individuals with neurocognitive disorder (NCD) may have a higher prevalence of sarcopenia features [3, 4].

Several definitions and diagnostic criteria for sarcopenia have been proposed over recent decades, with the first widely accepted being published in 2010 by the European Working Group on Sarcopenia in Older People (EWGSOP1) [5]. EWGSOP1 criteria differentiate presarcopenia,
a condition characterized solely by loss of lean mass, sarcopenia, characterized by loss of lean mass and muscle strength or physical performance, and severe sarcopenia, when all three are present [3]. In 2018, a revised version of these criteria has been published (EWGSOP2) [2]. According to EWGSOP2, low muscle strength is considered the primary indicator of sarcopenia, while the presence of both low muscle strength and low muscle mass is necessary to confirm the diagnosis, and a concomitant loss of physical performance is indicative of severe sarcopenia [2]. In addition, EWGSOP2 introduced novel recommendations to improve early detection of sarcopenia in clinical practice, suggesting that muscle strength be assessed if patients report symptoms or signs of sarcopenia (feeling weak, slow walking speed, difficulty rising from a chair or weight loss/muscle wasting), preferably documented through the SARC-F (Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls) questionnaire [2].

Recommendations on screening for sarcopenia are included also in the International Conference on Sarcopenia and Frailty Research guidelines, which suggested evaluating individuals aged 65 years or above annually or after the occurrence of major health events, by means of gait speed or SARC-F [6]. These indications mirror the growing awareness that a timely identification of sarcopenia is of the utmost importance, being the condition associated with negative health outcomes, including falls and fractures [7], mobility disorders and impairment in the activities of daily living [8], poor quality of life and mortality [9]. The SARC-F questionnaire and its abbreviated version (SARC-F-3) and the Mini Sarcopenia Risk Assessment Questionnaire and its abbreviated version (MSRA-5) are two widely used questionnaires for rapid sarcopenia screening in clinical practice [10, 11].

However, the number of studies investigating their accuracy in general population is still limited and, to the best of our knowledge, no studies have investigated their performance in patients with Alzheimer’s disease (AD), the most common type of dementia, where the prevalence of sarcopenia appears to be higher [4, 12]. Therefore, this study aims to fill this research gap by evaluating the performance of the SARC-F-3 and the MSRA-5 questionnaires in identifying sarcopenia in AD patients.

**Methods**

**Study design**

Single-center observational study.

**Study population**

We enrolled 130 consecutive elderly adults who attended the Center for Neurodegenerative Diseases and the Aging Brain of the University of Bari Aldo Moro in Tricase between January 2019 and January 2020 and received a final diagnosis of mild or major NCD due to probable AD, based on the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [13].

Fifty-two patients underwent lumbar puncture and showed evidence of AD pathophysiological process, thus presenting an increase level of diagnostic certainty according to the National Institute on Aging and Alzheimer’s Association (NIA-AA) diagnostic guidelines [14].

Exclusion criteria were active treatment for cancer or cancer diagnosis in the past five years, severe knee or hip osteoarthritis limiting mobility, inflammatory diseases, stroke with upper and/or lower extremity involvement, Parkinson’s disease or other neurological disorders likely to interfere with physical function and major psychiatric illnesses. Only patients who were able to perform the handgrip test three times for each hand were included. More specifically, among 148 screened subjects, 3 were excluded for oncological pathologies, 8 for serious osteoarticular pathologies, 2 for inflammatory pathologies, 1 for recent stroke and 4 for inability to perform the handgrip test. Written informed consent was obtained from patients or from patient’s legal guardians if the patients were not able to provide it.

**Sarcopenia screening**

SARC-F-3 and MSRA-5 were used to screen AD subjects regarding the risk of sarcopenia.

Participants’ relatives/caregivers were present when the questionnaires were administered and allowed to help them with the responses, whenever necessary.

SARC-F is a five-item questionnaire, based on cardinal features of sarcopenia namely strength, assistance in walking, rise from a chair, climbing stairs and falls [15]. SARC-F-3 is the short form of SARC-F, comprising three of the five original items (strength, climbing stairs, and assistance in walking). Scores range from 0 to 6, and a SARC-F-3 score equal or higher than 2 is suggestive of increased risk of sarcopenia [10].

MSRA-7 comprises 7 items assessing age, physical activity level, number of hospitalizations during the preceding year, weight loss, number of meals per day, milk and dairy products, and protein consumption. The reduced version (MSRA-5) does not include questions on number of meals and milk and dairy products consumption. Score ranges from 0 to 60 (0, 5, 10 or 15 points for each item), and a score equal or lower than 45 is suggestive of increased risk of sarcopenia [11].
Sarcopenia diagnosis

Sarcopenia was diagnosed according to EWGSOP1 and EWGSOP2 criteria, using their relative cut-off values for muscle mass and muscle strength [2, 5].

Skeletal muscle mass (SM) was estimated through a phase-sensitive single-frequency bioimpedance analyzer (BIA 101 Anniversary, Akern, Florence, Italy) [16]. Bioimpedance analysis was performed with the participant lying down on a testing table in a supine position and electrodes placed on the right hand and foot. Low muscle mass was defined as a Skeletal Muscle Index (SMI) computed as SM divided for height squared below or equal to 8.87 kg/m² for males and to 6.42 kg/m² for females for EWGSOP1, or as an appendicular skeletal muscle mass (ASM) below or equal to 20 kg for males and to 15 kg for females for EWGSOP2 [2, 5]. Muscle strength was evaluated through hand grip strength (HGS) using an electronic handheld dynamometer (DynX®, AKERN). HGS was assessed three times for each hand, alternating sides, and the best of the six grip strength measurements was registered. Low muscle strength was defined as an HGS below or equal to 20 kg for males and to 15 kg for females for EWGSOP1 and below or equal to 27 kg for males and to 16 kg for females for the EWGSOP2 criteria.

Statistical analysis

Data were explored with descriptive statistics (mean ± SD or percentage). Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and the area under the receiver operating characteristic curve (AUC) were calculated for SARC-F-3 and MSRA-5 according EWGSOP1 and EWGSOP2 criteria. Cohen's kappa (k) was used to assess the agreement between questionnaires. Statistical analyses were conducted using SPSS 19.0 (SPSS, Inc. Chicago, IL).

Results

Demographic, clinic, and anthropometric data are reported in Table 1.

Forty-three patients (33.1%) met the diagnostic criteria for mild NCD due to probable AD and eighty-seven (66.9%) met the criteria for major NCD due to probable AD. Regarding MMSE score, 12 patients (9.2%) have a score between 2–10, 52 (40%) between 11–20 and 66 (50.8%) between 21–30.

All patients were community-dwelling at the time of evaluation. Sarcopenia was diagnosed in thirty-one (23.8%) and six individuals (4.6%) according to the EWGSOP1 and EWGSOP2 criteria, respectively. Differences in demographic, clinic, and anthropometric data with respect to presence of sarcopenia are reported in Supplementary Table 1 and Supplementary Table 2. A higher prevalence of sarcopenia was observed with EWGSOP1 (23.8%) compared to EWGSOP2 (4.7%) while prevalence of sarcopenia was similar between patients with minor and major NCD, regardless of the diagnostic criteria adopted. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and the AUC for SARC-F-3 and MSRA-5 are reported in Table 2.

Table 1 Demographic, clinical characteristics and questionnaires score

|                          | Mean ± SD or Percentage | Range |
|--------------------------|-------------------------|-------|
| Male (%)                 | 59 (45.4%)              |       |
| Age, years               | 70.71 ± 8.50            | 52–90 |
| BMI, kg/m²               | 26.67 ± 4.14            | 18.12–39.26 |
| MMSE                     | 19.64 ± 6.26            | 2–30  |
| Mild NCD (%)             | 43 (33.1%)              |       |
| Major NCD (%)            | 87 (66.9%)              |       |
| HGS, kg                  | 19.31 ± 7.19            | 5–38.70 |
| SM, kg/m²                | 9.70 ± 1.78             | 5–14.88 |
| ASM, kg                  | 20.12 ± 4.41            | 11.60–34.30 |
| EWGSOP1                  |                         |       |
| Low muscle mass, (%)     | 35 (26.9%)              |       |
| Low muscle strength, (%) | 93 (71.5%)              |       |
| Sarcopenia, (%)          | 31 (23.8%)              |       |
| EWGSOP2                  |                         |       |
| Low muscle mass (%)      | 18 (13.8%)              |       |
| Low muscle strength (%)  | 70 (53.8%)              |       |
| Sarcopenia (%)           | 6 (4.6%)                |       |
| SARC-F-3                 | 0.72 ± 0.89             | 0–4   |
| MSRA-5                   | 53.81 ± 4.85            | 40–60 |

BMI Body Mass Index, MMSE Mini Mental State Examination, NCD Neurocognitive Disorder, HGS Hand Grip Strength, SMI Skeletal Muscle Index, ASM Appendicular Skeletal Muscle Mass, EWGSOP1 European Working Group on Sarcopenia in Older People of 2010, EWGSOP2 European Working Group on Sarcopenia in Older People of 2018, SARC-F-3 Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls questionnaire, 3-item version, MSRA-5 Mini Sarcopenia Risk Assessment questionnaire, 5-item version
a moderate agreement (κ = 0.53). More in detail 108 patients were identified as not at risk of sarcopenia by both SARC-F-3 and MSRA-5, 9 patients were identified as at risk of sarcopenia by both SARC-F-3 and MSRA-5, 11 patients were identified as at risk by SARC-F-3 and not at risk of sarcopenia by MSRA-5 while 2 patients were identified as at risk by MSRA-5 and not at risk by SARC-F-3.

**Discussion**

This is the first study that assessed the performance of SARC-F-3 and MSRA-5 in screening patients with AD regarding the risk of sarcopenia. Overall, we found that both questionnaires showed low sensitivity, moderate-to-high specificity, and low AUC. Considering that these questionnaires have been proposed as tools for sarcopenia screening in clinical practice, the low sensitivity makes them unsuitable in patients with AD.

SARC-F-3 has been developed by Woo et al. based on the evidence that a combination of three out of the five questions of the original SARC-F showed the highest area under the curve and are able to predict all the adverse health outcomes (physical limitation, length of hospital stays, and mortality), among community-dwelling individuals [10].

Nevertheless, a subsequent study that compared the performance of SARC-F-3 and SARC-F in community-dwelling elderly (mean age 71.5 ± 5.8 y, sarcopenia diagnosed according to the Asian Working Group for Sarcopenia criteria) [17], showed that the SARC-F-3 displayed lower sensitivity (13.1%), specificity (97.8%) and AUC (0.676, 95% CI: 0.627–0.723) compared to SARC-F.

The excellent specificity and poor sensitivity for sarcopenia detection that the SARC-F-3 showed in our sample of AD patients is consistent with the results of previous studies. However, up to now, no other studies have investigated its performance. On the other hand, several studies have assessed the performance of its extended version, among community-dwelling individuals. A recent metanalysis described that SARC-F has low-to-moderate sensitivity (28.9%–55.3%) and moderate-to-high specificity (68.9%–88.9%) and display slightly better accuracy than SARC-F-3 in identifying person at risk of sarcopenia. [18]

It has also been reported that the performance of SARC-F varies according to the specific diagnostic criteria adopted, with overall better performance observed with EWGSOP2 compared to EWGSOP1 [18–20]. Similarly, in our study the abbreviated version displayed greater sensitivity and specificity with EWGSOP2 (16.7% and 84.7%) than with EWGSOP1 criteria (9.7% and 82.8%). The

---

**Table 2** Diagnostic performances of SARC-F-3 and MSRA-5

|                | Sensitivity | Specificity | Positive Likelihood Ratio | Negative Likelihood Ratio |
|----------------|-------------|-------------|---------------------------|---------------------------|
| **SARC-F-3**   |             |             |                           |                           |
| Low muscle mass|             |             |                           |                           |
| EWGSOP1        | 8.6% (1.8–23.1) | 82.1% (72.9–89.2) | 0.48 (0.15–1.54) | 1.11 (0.97–1.28) |
| EWGSOP2        | 27.8% (9.7–53.5) | 86.6% (78.9–92.3) | 2.07 (0.86–5.01) | 0.8 (0.62–1.12) |
| Low muscle strength |             |             |                           |                           |
| EWGSOP1        | 17.2% (10.2–26.4) | 89.2% (74.6–96.9) | 1.59 (0.57–4.45) | 0.93 (0.80–1.07) |
| EWGSOP2        | 15.7% (8.1–26.4) | 85.0% (73.4–92.9) | 1.05 (0.47–2.36) | 0.99 (0.86–1.15) |
| Sarcopenia     |             |             |                           |                           |
| EWGSOP1        | 9.7% (2.0–25.8) | 82.8% (73.9–89.7) | 0.56 (0.18–1.80) | 1.09 (0.94–1.26) |
| EWGSOP2        | 16.7% (0.4–64.1) | 84.7% (77.1–90.5) | 1.09 (0.17–6.82) | 0.98 (0.68–1.42) |
| **MSRA-5**     |             |             |                           |                           |
| Low muscle mass|             |             |                           |                           |
| EWGSOP1        | 2.9% (0.1–14.9) | 89.5% (81.5–94.8) | 0.24 (0.04–2.04) | 1.09 (0.99–1.19) |
| EWGSOP2        | 22.2% (6.4–47.6) | 93.8% (87.6–97.5) | 3.56 (1.16–10.93) | 0.83 (0.65–1.07) |
| Low muscle strength |             |             |                           |                           |
| EWGSOP1        | 7.5% (3.1–14.9) | 89.2% (74.6–96.9) | 0.70 (0.22–2.24) | 1.04 (0.91–1.18) |
| EWGSOP2        | 2.9% (0.4–9.9) | 85% (73.4–92.9) | 0.19 (0.04–0.85) | 1.14 (1.02–1.28) |
| Sarcopenia     |             |             |                           |                           |
| EWGSOP1        | 3.2% (0.1–16.7) | 89.9% (82.2–95.1) | 0.32 (0.04–2.40) | 1.08 (0.98–1.18) |
| EWGSOP2        | 0% (0.0–45.9) | 91.1% (84.7–95.5) | 0  | 1.10 (1.04–1.16) |

EWGSOP1: European Working Group on Sarcopenia in Older People of 2010, EWGSOP2: European Working Group on Sarcopenia in Older People of 2018, SARC-F-3: Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls questionnaire, 3-item version, MSRA-5: Mini Sarcopenia Risk Assessment questionnaire, 5-item version.
differences in accuracy found using the two diagnostic criteria, as the different prevalence of sarcopenia, are likely attributable to the different cut-off points, more stringent for both muscle mass and muscle strength in EWGSOP2 compared to EWGSOP1. Nonetheless, further studies with a larger sample are needed to identify the factors associated to the differences in sarcopenia prevalence, as age, sex, cognitive performance, and functional ability.

The performance of SARC-F in patients with neurodegenerative diseases, so far, has been evaluated only in the study by da Luz et al. which administered the questionnaire to patients with Parkinson’s disease (mean age 68.9 ± 6.5 y, sarcopenia diagnosed according to EWGSOP1 and EWGSOP2) and reported lower sensitivity (27.2%-23.1%) and specificity (66.6%-68.1%) [21], compared to general population. Taken together, these results seem to suggest that SARC-F is more suitable for screening the risk of sarcopenia among hospitalized or nursing home elderly: indeed, community-dwelling elderly individuals are often able to perform most of the activities investigated by the questionnaire [22, 23]. The study by Cao et al. supports this view by showing that higher SARC-F scores are found in patients with older age, higher comorbidities and living in nursing homes [24].

Regarding MSRA-5, scientific literature is scant and generally carried out in community-dwelling elderly, with only few studies on hospitalized/institutionalized individuals. In community-dwelling individuals the MSRA-5 displayed a different sensitivity and specificity profile than SARC-F, presenting high sensitivity and moderate-high specificity (80.4% and 64.4%, respectively in the original validation study) [11].

Studies directly comparing MSRA-5 and SARC-F confirmed these differences, reporting similar diagnostic accuracy but higher sensitivity and lower specificity of MSRA-5 than SARC-F [25–27]. However, a very recent study showed that, when MSRA-5 is used to identify sarcopenia among hospitalized individuals, the specificity is significantly lower (16.3%), although sensitivity remains high (90.9%) [28]. Our results on elderly non-hospitalized AD patients are in line with the above-mentioned study, showing a very low sensitivity and high specificity of MSRA-5, regardless the diagnostic criteria adopted. Collectively, these results seem to suggest that MSRA-5’s performance is heavily influenced by clinical characteristics and living environment (community-dwelling vs hospitalized) of the population under examination. Therefore, the poor performance observed may be due to the fact that the characteristics investigated by the MSRA-5 are seldom presented by community-dwelling AD subjects. Finally, we found a moderate agreement between questionnaires (k = 0.53). Indeed, both questionnaires investigate complementary aspects of the same condition: SARC-F-3 evaluates subjective difficulties in physical performances, related to activity of daily living and muscle strength [29]; by contrast, MSRA-5 is based on objective indicators associated with increased risk of sarcopenia such as number of hospitalizations, activity level, age and nutrition [11].

In conclusion, the sensitivity and specificity profile found in our study indicates that a significant number of sarcopenic patients are misidentified by both SARC-F-3 and MSRA-5, thus not seem suitable as sarcopenia screening tools in AD.

Therefore, the development and validation of a reliable tool for sarcopenia detection in AD would be highly recommended, considering that individuals with cognitive decline are at increased risk of developing sarcopenia [30] and that this condition is potentially reversible through appropriate lifestyle changing interventions, mainly rehabilitation and proper nutrition [31, 32].

Several limitations of the present study should be acknowledged. First, physical performance was not evaluated, thus the prevalence of sarcopenia according to EWGSOP1 could be underestimated and the severity of sarcopenia (EGWSOP2) could not be assessed. Second, we use BIA to estimate muscle mass. Although BIA is mentioned among the techniques to estimate muscle mass in both the EWGSOP1 and EWGSOP2 criteria, the dual energy X-ray absorptiometry is the gold standard technique for quantifying muscle mass, due to its higher reproducibility and greater precision. Third, we did not administer the original version of the questionnaires but only their abbreviated version. Finally, sample size is relatively small, although in line with that reported in several single-center studies, and or results need to be confirmed on a larger cohort of patients.

**Conclusions**

SARC-F-3 and MSRA-5 do not seem suitable to screen AD patients regarding the risk of sarcopenia.

Considering that the prevalence of sarcopenia is high in AD, the development and validation of new screening tools that can be easily used in clinical practice is of paramount importance. In their absence, objective assessment of muscle mass, muscle strength, and physical performance is mandatory for correct identification of sarcopenia in AD patients.

**Abbreviations**

AD: Alzheimer’s Disease; ASM: Appendicular skeletal muscle mass; AUC: Area under the receiver operating characteristic curve; EWGSOP1: European Working Group on Sarcopenia in Older People of 2010; EWGSOP2: European Working Group on Sarcopenia in Older People of 2018; HGS: Hand grip strength; MSRA: Mini Sarcopenia Risk Assessment; MSRA-5: Mini Sarcopenia Risk Assessment – 5 items; NCD: Neurocognitive disorder; SARC-F: Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls; SARC-F-3: Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls – 3 items; SM: Skeletal muscle mass; SMI: Skeletal Muscle Index (SMI).
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12877-022-03441-5.

Additional file 1:

Acknowledgements
None.

Authors’ contributions
G.B.: conception of the study, interpretation of data, drafting the initial manuscript and revising it for important intellectual content. R.B.: acquisition of data, interpretation of data, reviewed the manuscript for intellectual content. M.R.B.: acquisition of data, data curation, reviewed the manuscript for intellectual content. C.Z.: data curation, interpretation of data, reviewed the manuscript for intellectual content. G.L.: conception of the study, statistical analysis, interpretation of data, drafting the initial manuscript and revising it for important intellectual content. G.L.: conception of the study, supervising, drafting the initial manuscript and revising it for important intellectual content. The author(s) read and approved the final manuscript.

Funding
This research was funded by Regione Puglia and CNR for Tecnopolo per la Medicina di Precisione (CUP - B8418000540002). D.G.R. n. 2117 of 21.11.2018.

Availability of data and materials
The dataset supporting the conclusions of this article is available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
The experimental protocol was approved by the ethics committee of ASL Lecco (verbal n° 6, July 25th, 2017) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

Consent for publication
Not applicable.

Competing interests
Giulia Bramato, Roberta Barone, Maria Rosaria Barulli, Chiara Zecca and Marco Filardi have no potential competing interest to disclose. Rosanna Tortelli is a full-time employee of F. Hoffmann-La Roche, Ltd, outside of the submitted work. Giancarlo Logroscino reports personal fees from Roche and Amplifon, outside of the submitted work.

Author details
1 Center for Neurodegenerative Diseases and the Aging Brain, University of Bari Aldo Moro at Pia Fondazione “Card. G. Panico”, Tricase, Italy. 2 Department of Geriatrics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, Rome, Italy. 3 Department of Basic Medicine, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.

Received: 26 April 2022 Accepted: 6 September 2022 Published online: 17 September 2022

References
1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia Lancet. 2019;393:2636–46.
2. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
3. Mayhew AJ, Amog K, Phillips S, Parise G, McNicholas PD, de Souza RJ, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses. Age Ageing. 2019;48:48–56.
4. Waite SJ, Maitland S, Thomas A, Yarnall AJ. Sarcopenia and frailty in individuals with dementia: a systematic review. Arch Gerontol Geriatr. 2021;92: 104268.
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.
6. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICF/SR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22:1148–61.
7. Yeung SSY, Reijniezerse EM, Pham VK, Trappenburg SAC, Lim WK, Meikers CGM, et al. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10:485–500.
8. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12:403–9.
9. Beaudart C, Biver E, Register J-Y, Rizzoli R, Rolland Y, Baumann J, et al. Validation of the Sarqol®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8:238–44.
10. Woo J, Yu R, Leung J. A 3-item SARC-F. J Am Med Dir Assoc. 2018;19:223–8.
11. Rossi AP, Meccioloro R, Rubello S, Fantin F, Caliani C, Zocco E, et al. Assessing the Risk of Sarcopenia in the Elderly: The Mini Sarcopenia Risk Assessment (MSRA) J Nutr Health Aging. 2017;21:743–9.
12. Yazar T, Olgun YH. The prevalence of sarcopenia and dynapenia according to stage among Alzheimer-type dementia patients. Ideggyogy Sz. 2019;72:171–9.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington, VA. 2013.
14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7:263–9.
15. Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15:630–4.
16. Scalfoglieri A, Clarys JP, Bauer JM, Verlaan S, Melderren LV, Vantieghem S, et al. Predicting appendicular lean and fat mass with bioelectrical impedance analysis in older adults with physical function decline – The PROVIDE study. Clin Nutr. 2017;36:869–75.
17. Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al. SARC-F for sarcopenia screening in community-dwelling older adults: Are 3 items enough? Medicine (Baltimore). 2018;97:e11726.
18. Voelker SN, Michalopoulos N, Maier AB, Reijniezerse EM. Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2021;22:1864-1876.e16.
19. Ida S, Kaneko R, Murata K. SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. J Am Med Dir Assoc. 2018;19:1685–9.
20. Lu J-L, Ding L-Y, Xu Q, Zhu S-Q, Xu X-Y, Hua H-X, et al. Screening Accuracy of SARC-F for Sarcopenia in the Elderly: A Diagnostic Meta-analysis. J Nutr Health Aging. 2021;25:172–82.
21. da Luz MCL, Pinho CPS, Bezerra GK de A, da Concepção Chaves de Lemos M, da Silva Diniz A, Cabral PC. SARC-F and SARC-CalF in screening for sarcopenia in older adults with Parkinson’s disease. Exp Gerontol. 2021;144:111183.
22. Kera T, Kawai H, Hirano H, Kojima M, Watanabe Y, Motokawa K, et al. Limitations of SARC-F in the diagnosis of sarcopenia in community-dwelling older adults. Arch Gerontol Geriatr. 2020;87:103959.
23. Gade J, Quick AA, Beck AM,阮等 F, Winther A. SARC-F in hospitalized, geriatric medical patients- Feasibility, prevalence of risk of sarcopenia, and characteristics of the risk group, including one-year follow-up. Clin Nutr ESPEN. 2020;37:80–6.
24. Cao L, Chen S, Zou C, Ding X, Gao L, Liao Z, et al. A pilot study of the SARC-F scale on screening sarcopenia and physical disability in the Chinese older people. J Nutr Health Aging. 2014;18:277–83.
25. Nishikawa H, Asai A, Fukushishi S, Takeuchi T, Goto M, Ogura T, et al. Screening Tools for Sarcopenia in Vivo. 2021;35:3001–9.
26. Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al. Comparing Mini Sarcopenia Risk Assessment With SARC-F for Screening Sarcopenia in Community-Dwelling Older Adults. J Am Med Dir Assoc. 2019;20:53–7.
27. Krzymińska-Siemaszko R, Tobis S, Lewandowicz M, Wieczorowska-Tobis K. Comparison of four sarcopenia screening questionnaires in community-dwelling older adults from Poland using six sets of international diagnostic criteria of sarcopenia. PLoS ONE. 2020;15: e0231847.

28. Rossi AP, Galliani C, Urbani S, Fantin F, Brandimarte P, Martini A, et al. Sarcopenia Risk Evaluation in a Sample of Hospitalized Elderly Men and Women: Combined Use of the Mini Sarcopenia Risk Assessment (MSRA) and the SARC-F. Nutrients. 2021;13:635.

29. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28–36.

30. Chang K-V, Hsu T-H, Wu W-T, Huang K-C, Han D-S. Association Between Sarcopenia and Cognitive Impairment: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2016;17:1164.e7-1164.e15.

31. Beckwée D, Delaere A, Aelbrecht S, Baert V, Beaudart C, Bruyère O, et al. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. J Nutr Health Aging. 2019;23:494–502.

32. Robinson S, Granic A, Sayer AA. Nutrition and Muscle Strength, As the Key Component of Sarcopenia: An Overview of Current Evidence. Nutrients. 2019;11:E2942.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.